We are international
Donate
• IMF TV TEXT SIZE   
webcasts from medical meetings    back

The IMF is pleased to provide you with a broad sampling of myeloma presentations and posters from the 2004 annual meeting of the American Society of Hematology in San Diego, California. We hope you will find this material informative and useful.

ASH 2004 Presentations and Posters
    next      view all

THERAPIES FOR PREVIOUSLY UNTREATED PATIENTS
ASH 2004: Assoc. Prof. S.Vincent Rajkumar, MD
Combination Therapy with CC-5013 (Lenalidomide; RevlimidTM) plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma

A Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00): A Trial Coordinated by the Eastern Cooperative Oncology Group

ASH 2004: Sundar Jagannath, MD
Bortezomib as First-Line Therapy in Patients with MM; A Multicenter Phase 2 Clinical Trial

ASH 2004: Paul G. Richardson, MD
Phase 2 Clinical Trial of Single Agent Bortezomib in Patients with Previously Untreated Multiple Myeloma.

ASH 2004: Prof. Thierry Facon, MD
Randomized Trial Comparing MP, MP-THAL and MEL100 for Newly Diagnosed Pts Aged 65-75 Years

ASH 2004: Asst. Prof. Michael Wang, MD
VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.

ASH 2004: Prof. Jesus San Miguel
A Phase I/II National Multicenter Open-label Study of Bortezomib Plus Melphalan and Prednisone in Elderly Untreated Multiple Myeloma Patients

ASH 2004: Prof. Meletios-Athanassios Dimpopoulos, MD
Primary Treatment with Pulsed Melphalan, Dexamethasone, Thalidomide (MDT) for Symptomatic Patients with Multiple Myeloma Who Are 75 Years of Age or Older.

ASH 2004: Prof. Morie A. Gertz, MD
A Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00)

A new trial (E4A03) just opening to look at Revlimid vs. Thalidomide and standard dose vs. lower dose Dexamethasone

ASH 2004: Antonio Palumbo, MD
MPT vs MP: INTERIM ANALYSIS PROSPECTIVE RANDOMIZED TRIAL NEWLY DIAGNOSED PATIENTS AGE > 65 YEARS

THERAPIES FOR RELAPSING PATIENTS
ASH 2004: Rubin Niesvizky, MD
Depsipeptide in the Treatment of Relapsed and Refractory Multiple Myeloma (MM): A Prospective Evaluation of the Cell Cycle

    next      view all